CHU Helora

The Department of Endocrinology at CHU Helora is conducting research focused on Severe Hypertriglyceridemia, aiming to evaluate new therapeutic approaches that lower triglyceride levels and improve metabolic health.

• Evaluation of novel agents that reduce fasting serum triglycerides
• Assessment of safety and tolerability in metabolic disorder patients
• Long‑term impact on cardiovascular risk markers

These studies seek to provide better treatment options for patients with high triglyceride levels, addressing a key metabolic challenge.

Research at CHU Helora also explores the interplay between metabolic dysfunction and respiratory physiology, investigating how systemic metabolic disorders affect lung health.

• Study of metabolic biomarkers in patients with respiratory conditions
• Impact of lipid‑lowering therapies on pulmonary function
• Integration of endocrine and respiratory care pathways

The goal is to improve diagnostic and therapeutic strategies for patients where metabolic and respiratory issues intersect.

The site’s interdisciplinary trials examine circulatory and respiratory physiological processes in the context of both metabolic disease and hematologic malignancy such as relapsed or refractory diffuse large B‑cell lymphoma.

• Comparison of overall survival outcomes across treatment regimens
• Evaluation of cardiovascular effects of oncology therapies
• Analysis of physiological responses to combined metabolic and cancer treatments

By linking endocrine, cardiovascular, and oncologic research, the program aims to enhance patient management across multiple disease domains.